Lester & Sue Smith Breast Center at Baylor College of Medicine
Welcome,         Profile    Billing    Logout  
 18 Trials 
25 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ellis, Matthew J
FALCON, NCT01602380 / 2011-006326-24: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Active, not recruiting
3
462
Europe, Canada, Japan, US, RoW
faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
AstraZeneca
Hormone Receptor Positive Breast Cancer
04/16
08/27
Rimawi, Mothaffar
NCT02003209: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Active, not recruiting
3
315
US
Aromatase Inhibition Therapy, Aromatase Inhibition, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cytology Specimen Collection Procedure, Cytologic Sampling, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Whole Breast Irradiation
National Cancer Institute (NCI), NRG Oncology
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
10/16
12/25
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting
2
128
US
Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin
Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline
Breast Cancer
11/14
01/26
TACTIC, NCT03093350: - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

Active, not recruiting
2
12
US
TAA-specific CTLs
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, National Cancer Institute (NCI), Cancer Prevention Research Institute of Texas
Breast Cancer
05/19
05/25
CADENCE, NCT02547987: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

Active, not recruiting
2
25
US
Docetaxel, Taxotere, Carboplatin, Paraplatin
Mothaffar Rimawi
Breast Cancer
06/19
09/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
EA1181, NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Active, not recruiting
2
2175
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
RESPONSE, NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
SIMPHONY, NCT03324425: Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Active, not recruiting
2
5
US
Simvastatin 80mg, Zocor
Baylor Breast Care Center
Breast Cancer Stage IV
12/28
12/30
NCT03950570: ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Completed
1/2
58
US
Abraxane, ORIN1001
Orinove, Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
01/23
01/23
Osborne, C Kent
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
Nangia, Julie
ICE COMPRESS, NCT05642611: Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Recruiting
3
777
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cryocompression Therapy, Pneumatic Compression Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Malignant Solid Neoplasm
08/30
08/31
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
Canada, US, RoW
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
Canada, US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
TBCRC 037, NCT02206984: Endocrine Response in Women with Invasive Lobular Breast Cancer

Completed
2
201
US
Tamoxifen, Anastrozole, Fulvestrant
Priscilla McAuliffe
Breast Cancer
07/24
07/24
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
NCT01986140: Scalp Cooling to Prevent Chemo-induced Hair Loss

Active, not recruiting
N/A
236
US
PAXMAN Orbis Scalp Cooler, Control No treatment, No intervention
Julie Nangia
Breast Cancer, Alopecia
02/17
12/22
Niravath, Polly
REVIVE, NCT01984138: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Active, not recruiting
2
44
US
ESTRING, (estradiol vaginal ring), Replens
Polly A. Niravath, MD
Estrogen Receptor Positive Breast Cancer, Breast Cancer
12/24
12/25
NCT05305924: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Recruiting
2
28
US
Fulvestrant Run-In, Abemaciclib, Fulvestrant
The Methodist Hospital Research Institute, Eli Lilly and Company
ER-Positive Breast Cancer, HER2-negative Breast Cancer
12/25
12/26
DTP Trial, NCT03820141: Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Active, not recruiting
2
39
US
Durvalumab, IMFINZI, MEDI4736, Trastuzumab, Herceptin, Pertuzumab, Perjeta
The Methodist Hospital Research Institute, AstraZeneca
Breast Cancer
10/24
12/25
NCT05660083: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Recruiting
2
36
US
L-NMMA, iNOS inhibitor
The Methodist Hospital Research Institute, Novartis Pharmaceuticals
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
12/26
12/28
NCT03742245: Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer

Recruiting
1
28
US
Olaparib, AZD2281, KU-0059436, Lynparza, Vorinostat, Suberanilohydroxamic acid, Zolinza
The Methodist Hospital Research Institute, AstraZeneca, Merck Sharp & Dohme LLC
Breast Cancer Metastatic, Breast Cancer
09/25
03/26
Knezevic, Jana
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ellis, Matthew J
FALCON, NCT01602380 / 2011-006326-24: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Active, not recruiting
3
462
Europe, Canada, Japan, US, RoW
faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
AstraZeneca
Hormone Receptor Positive Breast Cancer
04/16
08/27
Rimawi, Mothaffar
NCT02003209: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Active, not recruiting
3
315
US
Aromatase Inhibition Therapy, Aromatase Inhibition, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cytology Specimen Collection Procedure, Cytologic Sampling, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Whole Breast Irradiation
National Cancer Institute (NCI), NRG Oncology
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
10/16
12/25
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting
2
128
US
Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin
Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline
Breast Cancer
11/14
01/26
TACTIC, NCT03093350: - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

Active, not recruiting
2
12
US
TAA-specific CTLs
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, National Cancer Institute (NCI), Cancer Prevention Research Institute of Texas
Breast Cancer
05/19
05/25
CADENCE, NCT02547987: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

Active, not recruiting
2
25
US
Docetaxel, Taxotere, Carboplatin, Paraplatin
Mothaffar Rimawi
Breast Cancer
06/19
09/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
EA1181, NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Active, not recruiting
2
2175
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
RESPONSE, NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
SIMPHONY, NCT03324425: Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Active, not recruiting
2
5
US
Simvastatin 80mg, Zocor
Baylor Breast Care Center
Breast Cancer Stage IV
12/28
12/30
NCT03950570: ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Completed
1/2
58
US
Abraxane, ORIN1001
Orinove, Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
01/23
01/23
Osborne, C Kent
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
Nangia, Julie
ICE COMPRESS, NCT05642611: Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Recruiting
3
777
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cryocompression Therapy, Pneumatic Compression Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Malignant Solid Neoplasm
08/30
08/31
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
Canada, US, RoW
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
Canada, US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
TBCRC 037, NCT02206984: Endocrine Response in Women with Invasive Lobular Breast Cancer

Completed
2
201
US
Tamoxifen, Anastrozole, Fulvestrant
Priscilla McAuliffe
Breast Cancer
07/24
07/24
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Active, not recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
01/26
06/26
NCT01986140: Scalp Cooling to Prevent Chemo-induced Hair Loss

Active, not recruiting
N/A
236
US
PAXMAN Orbis Scalp Cooler, Control No treatment, No intervention
Julie Nangia
Breast Cancer, Alopecia
02/17
12/22
Niravath, Polly
REVIVE, NCT01984138: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Active, not recruiting
2
44
US
ESTRING, (estradiol vaginal ring), Replens
Polly A. Niravath, MD
Estrogen Receptor Positive Breast Cancer, Breast Cancer
12/24
12/25
NCT05305924: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Recruiting
2
28
US
Fulvestrant Run-In, Abemaciclib, Fulvestrant
The Methodist Hospital Research Institute, Eli Lilly and Company
ER-Positive Breast Cancer, HER2-negative Breast Cancer
12/25
12/26
DTP Trial, NCT03820141: Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Active, not recruiting
2
39
US
Durvalumab, IMFINZI, MEDI4736, Trastuzumab, Herceptin, Pertuzumab, Perjeta
The Methodist Hospital Research Institute, AstraZeneca
Breast Cancer
10/24
12/25
NCT05660083: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Recruiting
2
36
US
L-NMMA, iNOS inhibitor
The Methodist Hospital Research Institute, Novartis Pharmaceuticals
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
12/26
12/28
NCT03742245: Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer

Recruiting
1
28
US
Olaparib, AZD2281, KU-0059436, Lynparza, Vorinostat, Suberanilohydroxamic acid, Zolinza
The Methodist Hospital Research Institute, AstraZeneca, Merck Sharp & Dohme LLC
Breast Cancer Metastatic, Breast Cancer
09/25
03/26
Knezevic, Jana
No trials found

Download Options